Clinical trials · Texas
Refractory Solid Tumors clinical trials in Texas
We’re tracking 117 recruiting refractory solid tumors studies with a site in Texas — including Phase 1 and Phase 1/Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Dallas, TexasAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Houston, TexasAges 18 years+ - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Houston, TexasAges 18 years+ - NCT06607939RecruitingPhase 1
Study of ORB-021 for advanced solid tumors
This trial tests a new drug called ORB-021 for people with advanced solid tumors that have come back or not responded to other treatments. The goal is to see if ORB-021 is safe and how it affects the body.
Houston, TexasAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Dallas, TexasAges 6 months–17 years - NCT06723236RecruitingPhase 1
Study of MGC028 for Advanced Solid Tumors
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
San Antonio, TexasAges 18 years+ - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07166601RecruitingPhase 1
Study of a drug for advanced solid tumors with MUC-1 marker
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
San Antonio, TexasAges 18 years+ - NCT07360314RecruitingPhase 1
A new drug targeting Ly6E for advanced solid tumors
This trial tests a new drug called M7437 that targets a protein (Ly6E) found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Galveston, TexasAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Galveston, TexasAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
San Antonio, TexasAges 18 years+ - NCT06115642Enrolling by invitationPhase 1
Study of HLX43 for advanced solid tumors
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
Houston, TexasAges 18–75 - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
San Antonio, TexasAges 18 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Dallas, TexasAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06752681RecruitingPhase 1
Testing day301 for advanced solid tumors
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
Houston, TexasAges 18 years+ - NCT07252479RecruitingPhase 1
Testing a new RAS inhibitor for advanced solid tumors
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
San Antonio, TexasAges 18 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Houston, TexasAges 18 years+ - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Austin, TexasAges 18 years+ - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Houston, TexasAges 1 month–17 years - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 1 month–17 years - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Irving, TexasAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Antonio, TexasAges 18 years+
Refractory Solid Tumors trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting refractory solid tumors studies listed above.
- The University of Texas MD Anderson Cancer Center · 11 studies
- NEXT Oncology · 9 studies
- START San Antonio · 3 studies
- Mary Crowley Cancer Research · 2 studies
- University of Texas Southwestern Medical Center · 2 studies
- Baylor University Medical Center
- Call for Information (Investigational Site 0054)
- GSK Investigational Site
What taking part in a refractory solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there refractory solid tumors clinical trials in Texas?
- Yes. We're currently tracking 117 recruiting refractory solid tumors studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory solid tumors study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory solid tumors studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.